Objective: To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.
Aridis Pharmaceuticals announced top-line results from the AR-301-002 Phase III study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR 301 (salvecin) with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).
Introduction: The aim of this study was to evaluate the clinical outcomes and safety of daptomycin therapy in patients with serious Gram-positive infections.
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by...
Zyvox (linezolid) from Pfizer may be more effective than the antibiotic vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus...
Theravance Biopharma, Inc. announced new positive data from several studies of Vibativ (telavancin) confirming the product's in vitro potency against...
The Advisory Committee (AIDAC) of the FDA has voted 9-6 that data, from Theravance relative to Vibativ (telavancin), failed to...
Basilea Pharmaceutica Ltd. has announced the start of a clinical phase III study with its antibiotic ceftobiprole. The registration study...
For over a century, acute 'post-streptococcal glomerulonephritis' (APSGN) was the prototypical form of bacterial infection-associated glomerulonephritis, typically occurring after resolution of infection and a distinct infection-free latent period.
Melinta Therapeutics, LLC announced that the FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).